Monopar Therapeutics
MNPR
10 hedge funds and large institutions have $471K invested in Monopar Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.02% less ownership
Funds ownership: 1.56% → 1.55% (-0.02%)
8% less capital inflows, than outflows
Capital inflows: $33K | Capital outflows: $35.9K
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rappaport Reiches Capital Management
Skokie`,
Illinois
|
+$26.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.64K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$232 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
| 2 |
IFP Advisors
Tampa,
Florida
|
-$13K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.48K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$732 |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$720 |
MNPR Hedge Fund Activity: Q4 2022 in Review
10 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q4 2022, worth a combined $471K — up 50% from $314K a quarter earlier.
Fund positioning in MNPR was balanced in Q4 2022: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Rappaport Reiches Capital Management, opening a new position worth an estimated $26.1K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $16K sold.
- 10 institutional investors held Monopar Therapeutics (MNPR) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $471K of Monopar Therapeutics stock for Q4 2022, up 50% quarter-over-quarter.
- 2 funds opened new Monopar Therapeutics positions in Q4 2022 and 2 closed out, a net change of 0 holders.
- The largest Monopar Therapeutics buyer in Q4 2022 was Rappaport Reiches Capital Management, an estimated $26.1K added.
- The largest Monopar Therapeutics seller in Q4 2022 was Susquehanna International Group, an estimated $16K sold.
Based on aggregated 13F filings for Q4 2022.